Medtronic’s Micra TPS shows effectiveness in real-world study

Medtronic has announced preliminary results from a real-world study that demonstrates the strong performance of its Micra transcatheter pacing system (TPS).

Data from the global Micra TPS Post-Approval Registry showed a 99.6 percent implant success rate associated with the device and a 1.51 percent rate of major complications after 30 days in a diverse patient population.

This registry drew upon data from 795 patients treated by 149 physicians at 97 centres across 20 countries worldwide, and assessed rates of complications up to 30 days following implant.

Dr Rob Kowal, vice-president and medical director of Medtronic's cardiac rhythm and heart failure division, said: "This positive early data in the post-market setting reinforces the careful attention that went into the design of the Micra TPS, and the rigorous training programme we have put in place for new implanting physicians of the device."

Micra TPS is marketed as the world's smallest pacemaker, measuring around the same size as a large vitamin. It is less than one-tenth the size of traditional pacemakers, and does not require leads or a surgical pocket under the skin.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.